Study of a drug for SLC6A1-related seizures
Part of Brain & nervous system clinical trials.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of an SLC6A1-related disorder (a specific gene change).
- You are between 2 and 60 years old.
- You have had at least 4 seizures in the last 4 weeks.
- You have tried at least 2 seizure medicines that didn't fully control your seizures.
- You have been on the same seizure medicine dose for at least 4 weeks before starting.
- You have a doctor who can order lab tests and an EEG, and a caregiver who speaks English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.
This study tracks how children with SLC6A1 genetic mutations develop over time. Researchers will collect information about seizures, development, and daily functioning to better understand the condition and help guide future treatments.
This study follows children with Dravet syndrome caused by a specific SCN1A gene change to understand how the condition develops over time. It may help families know more about what to expect.
This study looks at “GABA signals” in the body/brain to learn more about Dravet syndrome and how it may relate to seizures. If you have Dravet syndrome caused by a specific SCN1A gene change, you may be asked to provide genetic test results and help with study visits so researchers can compare biomarker readings.
This study follows people with SLC13A5 deficiency to better understand how the condition changes over time, using surveys and clinical check-ins done remotely. If you (or your child) have this genetic condition, it may help researchers learn what symptoms to expect and how to track them.
Hear when a new SLC6A1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.